Business Context and Reporting Period
This Form 10-QSB covers the quarterly period ended March 31, 2005, for Orthodontix, Inc. (Note: The input metadata referenced "Protalix Biotherapeutics, Inc.", but the filing text explicitly identifies the issuer as Orthodontix, Inc.). The Company is a shell entity that terminated its affiliation with its founding orthodontic practices in 2001. It currently has no active operating business and is devoting its resources to identifying and consummating a merger or acquisition with an operating company.
Key Financial Metrics
| Metric | Q1 2005 | Q1 2004 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(10,358) | $(26,693) |
| Loss Per Share (Basic & Diluted) | $(0.00) | $(0.01) |
| Cash and Cash Equivalents (End of Period) | $533,190 | $113,258 |
| Total Liabilities | $69,412 | Filing text does not provide a clear value |
| Accumulated Deficit | $(3,748,109) | Filing text does not provide a clear value |
| Net Cash Used in Operating Activities | $(30,522) | $(66,221) |
Material Changes vs. Prior Period
- Reduced Net Loss: The net loss decreased significantly from $26,693 in Q1 2004 to $10,358 in Q1 2005, primarily due to a reduction in general and administrative expenses from $29,684 to $10,863.
- Improved Liquidity: Cash and cash equivalents increased substantially from $113,258 in March 2004 to $533,190 in March 2005.
- Lower Operating Burn: Net cash used in operating activities decreased from $66,221 to $30,522, indicating improved cost management.
Outlook, Risks, and Management Commentary
- Plan of Operation: Management intends to continue seeking a business combination (merger or acquisition) in sectors such as aircraft maintenance, health care, pharmaceuticals, or financial services. No specific target or contractual commitment exists.
- Liquidity: The Company believes its current cash reserves are sufficient to fund operations for at least the next twelve months.
- Risks: There is no assurance that the Company will successfully consummate a business combination or that the combined entity will be profitable. The Company has an accumulated deficit of approximately $3.75 million.
- Controls: Management concluded that disclosure controls and procedures were effective as of March 31, 2005, with no significant changes in internal controls.
- Accounting Updates: The Company is evaluating the impact of SFAS 123 (revised 2004) regarding share-based payments, effective for the fiscal year ending 2005.
Investor Verification Checklist
- Verify the Company's current cash balance and burn rate to confirm the "12-month runway" assertion.
- Confirm the status of any ongoing merger or acquisition negotiations, as none are currently disclosed.
- Review the $433,080 in bank deposits held in excess of federally insured limits for potential concentration risk.
- Monitor for any material changes in the accumulated deficit or the issuance of new equity to fund future operations.